Lisette Hilton
Abstract
The FDA approved Taltz (ixekizumab, Eli Lilly and Company) injection 80 mg/mL March 22 for treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Learn more
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The FDA approved Taltz (ixekizumab, Eli Lilly and Company) injection 80 mg/mL March 22 for treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Learn more
Key concepts: Ixekizumab, Plaque psoriasis, Medicine, Psoriasis, Dermatology, Secukinumab, Psoriatic arthritis